BioCentury
ARTICLE | Company News

OncoFusion Therapeutics, Medivation deal

January 25, 2016 8:00 AM UTC

OncoFusion will reacquire rights to its compounds targeting BET bromodomain proteins identified and developed with Medivation under a 2014 deal. OncoFusion said it plans to advance at least one compo...